Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
908 DevicesMASS +7.12%73 3-Year Share Buyback Ratio is -4.50 as of Mar. 2026. GuruFocus rates MASS with a GF Score™ of 73/100 and a GF Value™ of $7.09 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 613 Medical Devices & Instruments companies, 908 Devices ranks worse than 57.59% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. 908 Devices's current 3-Year Share Buyback Ratio was -4.50%.
The historical rank and industry rank for 908 Devices's 3-Year Share Buyback Ratio or its related term are showing as below:
MASS'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -7.1 Med: -6 Max: -4.1
Current: -4.5
During the past 8 years, 908 Devices's highest 3-Year Share Buyback Ratio was -4.10%. The lowest was -7.10%. And the median was -6.00%.
MASS's 3-Year Share Buyback Ratio is ranked worse than 57.59% of 613
companies
in the Medical Devices & Instruments industry
Industry Median: -2.6
vs MASS: -4.50
908 Devices (NAS:MASS) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
908 Devices 3-Year Share Buyback Ratio Related Terms
MASS vs ELMD, SGHT, LAB: 3-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, 908 Devices's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
908 Devices 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where 908 Devices's 3-Year Share Buyback Ratio falls into.
908 Devices 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -4.50 mean?
908 Devices (MASS) has a 3-Year Share Buyback Ratio of -4.50 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for 908 Devices and its competitors. According to the industry distribution chart, 908 Devices ranks #353 out of 613 companies in the Medical Devices & Instruments industry, placing it in the top 57.6%.
Is 908 Devices' 3-Year Share Buyback Ratio too high?
908 Devices' current 3-Year Share Buyback Ratio is -4.50. Based on the distribution chart, 908 Devices ranks #353 out of 613 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, 908 Devices has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 908 Devices' 3-Year Share Buyback Ratio compare to ELMD and SGHT?
According to the Medical Devices & Instruments industry distribution chart, 908 Devices ranks #353 out of 613 companies for 3-Year Share Buyback Ratio. This places 908 Devices in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for 908 Devices and its competitors. 908 Devices's current 3-Year Share Buyback Ratio is -4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 908 Devices stock overvalued right now?
Based on GuruFocus' analysis, 908 Devices (MASS) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.09, compared to a current price of $8.88 — trading 25.2% above its estimated fair value. The current 3-Year Share Buyback Ratio is -4.50. 908 Devices' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For 908 Devices (MASS), the current 3-Year Share Buyback Ratio is -4.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 908 Devices (MASS) Overvalued in 2026?
Based on GuruFocus' analysis, 908 Devices stock appears to be overvalued.
The current stock price of $8.88 is trading 25.2% above its estimated GF Value™ of $7.09.
GuruFocus considers 908 Devices to be Modestly Overvalued.
Key valuation signals for MASS:
3-Year Share Buyback Ratio: -4.50
GF Value™: $7.09 vs. price of $8.88 (25.2% above fair value)
No single metric tells the full story. See the MASS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
73GF Score
Get the complete analysis for MASS
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MASS has been successfully added to your 
